Test Price
700 AED✅ Home Collection Available
FGFR3/IgH Translocation FISH Test in UAE | 700 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary: The FGFR3/IgH Fluorescence In-Situ Hybridization (FISH) test is the gold-standard molecular cytogenetic assay for detecting the t(4;14) translocation in multiple myeloma, a high-risk genetic marker present in approximately 15% of cases. Performed at DNA Labs UAE (DHA License No. 1143), this ISO 9001:2015 certified assay (Certificate No. INT/EGQ/2509DA/3139) delivers 99.9% diagnostic sensitivity. The comprehensive service includes extraction within an accredited hospital facility, post-result telephonic consultation with a DHA-licensed genetics specialist, and direct insurance verification via WhatsApp at +971545488731. The cost is 700 AED with results available within 3–4 working days.
Test Overview & Methodology
The FGFR3/IgH FISH test directly detects the fusion of the fibroblast growth factor receptor 3 gene on chromosome 4 with the immunoglobulin heavy chain locus on chromosome 14, producing the t(4;14) rearrangement. This abnormality drives tumor proliferation and confers an adverse prognosis in multiple myeloma, making its identification essential for risk stratification and treatment planning. The assay uses dual-color fluorescent probes targeting breakpoint regions; when the red and green signals merge into a single yellow fusion signal, the translocation is confirmed. Results are reported with a quantitative signal pattern analysis and interpreted alongside bone marrow morphology, serum protein electrophoresis, and clinical parameters.
| Feature | Our FGFR3/IgH FISH | Traditional Karyotyping |
|---|---|---|
| Methodology | Fluorescence In‑Situ Hybridization (FISH) | Conventional G‑banding |
| Detection Resolution | Specific t(4;14) fusion, high sensitivity (>99.5%) | Low resolution; often misses cryptic translocations |
| Turnaround Time | 3–4 working days | 7–14 days (culture required) |
| Sample Requirement | Bone marrow aspirate or peripheral blood | Bone marrow (viable cells required) |
| Clinical Relevance | Directly guides high‑risk myeloma therapy decisions | General genetic screening; not translocation‑specific |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (DHA Registration ID: 9294403), Consultant Medical Genetics, provides clinical guidance:
The FGFR3/IgH FISH assay is a high-resolution molecular tool that reliably identifies the t(4;14) rearrangement with analytical sensitivity exceeding 99.5%. A positive fusion signal confirms the presence of this high-risk clone in the plasma cell population, but the result must never be interpreted in isolation. Comprehensive risk assessment requires integration with cytogenetic panel data, serum free light chain ratios, and the Revised International Staging System score. I recommend every patient schedule a dedicated discussion with their treating haematologist to contextualize the genetic finding before any therapeutic modifications are considered.
Important Advisory
Do not discontinue any prescribed medication, alter your treatment regimen, or initiate new therapies based solely on this test result. All clinical decisions must be made by your treating physician following a complete diagnostic workup.
Patient Safety Exclusions & Emergency Indicators
- This test is specifically indicated for suspected or confirmed plasma cell disorders under the supervision of a haematologist or oncologist. It is not intended for routine pre-surgical clearance, pregnancy fitness certification, or travel health screening.
- Patients with severe thrombocytopenia (platelet count < 20,000/µL) or uncorrected coagulopathy require physician clearance and platelet support before bone marrow sampling.
- If you experience sudden severe bone pain, pathological fractures, new-onset lower extremity weakness or numbness, loss of bladder or bowel control, or symptoms of hypercalcemia (confusion, extreme thirst, nausea, muscle weakness), seek emergency medical attention immediately.
Patient FAQ & Clinical Guidance
1. What exactly does the FGFR3/IgH FISH test detect?
The FGFR3/IgH FISH test identifies the t(4;14) translocation, an adverse-risk genetic marker in multiple myeloma. It uses fluorescent probes targeting the FGFR3 gene on chromosome 4 and the IgH locus on chromosome 14. When the two signals merge into a fusion signal, it confirms the rearrangement, classifying the myeloma as high-risk. This finding guides oncologists toward aggressive therapies such as proteasome inhibitor combinations and autologous stem cell transplantation, improving long-term survival outcomes.
2. Do I need to fast or stop medications before the test?
No fasting or dietary restrictions are required for the FGFR3/IgH FISH test on bone marrow or blood samples. Continue all prescribed medications unless your haematologist specifically advises otherwise. The test requires a valid physician prescription and is not applicable for pregnancy, travel, or surgical clearance purposes.
3. How accurate is the FGFR3/IgH FISH result?
Our ISO-accredited laboratory achieves 99.9% diagnostic sensitivity for t(4;14) detection using validated dual-color probe sets. FISH directly visualizes the gene fusion on intact interphase cells, minimizing false-positive rates. However, results must be interpreted alongside conventional cytogenetics and complete clinical findings to establish a comprehensive risk profile and guide treatment decisions.
4. How is the sample collected and what are the logistics?
Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. The procedure involves a bone marrow aspiration performed by a qualified medical professional under sterile conditions. For peripheral blood FISH, a standard venipuncture is performed at the hospital. Specimens are transported via secure cold-chain logistics to the laboratory for processing.
UAE Regulatory & Data Privacy Adherence
This diagnostic service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring all genetic and clinical data are encrypted, anonymized where applicable, and stored within secured UAE-based servers. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is licensed by the Dubai Health Authority (DHA License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE) and maintains ISO 9001:2015 certification for quality management systems.
Clinical & Logistical Metadata
| Test Name | FGFR3/IgH (Multiple Myeloma) FISH Translocation Test |
| Price (AED) | 700 AED |
| Turnaround Time | 3–4 Working Days |
| Sample Type / Matrix | Bone Marrow Aspirate (primary) or Peripheral Blood (alternative) |
| Methodology Used | Fluorescence In-Situ Hybridization (FISH) – Dual-Color Breakapart Probe Set |
| ICD-10-CM Code | C90.00 |
| LOINC Code | 48018-6 |
| DHA Facility License | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE · DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians